Jasper Therapeutics(US:JSPR) Globenewswire·2025-11-13 20:30Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is November 18, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which negatively impacted the prospects of its products, including briquilimab [5] - The failure to disclose these issues allegedly led to inflated business and financial prospects, resulting in investor damages when the truth was revealed [5]